Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature

Roberta D'Ambrosio, Alessio Aghemo, Valeria Rossetti, Rosaria Carrinola, Massimo Colombo

Research output: Contribution to journalArticle


Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.

Original languageEnglish
Pages (from-to)1585-1589
Number of pages5
JournalLiver International
Issue number11
Publication statusPublished - Nov 1 2016



  • direct acting antivirals
  • hepatitis C virus
  • immunosuppression
  • lung transplant
  • sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Cite this